Recap: scPharmaceuticals Q3 Earnings
Portfolio Pulse from Benzinga Insights
scPharmaceuticals (NASDAQ:SCPH) reported its Q3 earnings, missing estimated earnings by 13.89% with an EPS of $-0.41 versus an estimate of $-0.36. However, revenue was up $3.80 million from the same period last year. Last quarter, the company beat EPS estimates which led to a 1.29% increase in the share price the next day.
November 08, 2023 | 9:25 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
scPharmaceuticals missed Q3 earnings estimates but reported a YoY revenue increase. Last quarter's EPS beat led to a share price increase.
scPharmaceuticals missed its Q3 earnings estimates, which could negatively impact investor sentiment and potentially lead to a short-term decrease in the stock price. However, the company reported a YoY revenue increase, which is a positive sign. Additionally, the company's stock price increased after it beat EPS estimates last quarter, suggesting that the market reacts strongly to its earnings reports.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100